[March 25, 2015]

Research and Markets: H3N2 Infection Therapeutics Pipeline Review 2015 - 10 Companies & 16 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/pqmmkr/h3n2_infection) has announced the addition of the "H3N2 Infection - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• AlphaVax, Inc.
• Colby Pharmaceutical Company
• Crucell N.V.
• Cure Lab, Inc.
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson
• NanoViricides, Inc.
• REPLICor Inc.
• Takeda Pharmaceutical Company Limited
• Vaxart, Inc.

Drug Profiles

• Aspidasept
• AVX (News - Alert)-502
• bordetella pertussis [strain BPZE1] vaccine
• C-05
• CLVax-1.0
• CR-9114
• Gamma-Flu
• ID-38
• influenza [H3N2] vaccine
• influenza vaccine
• JVRS-100 + influenza [H1N1/H3N2] vaccine
• NVINF-1
• NVINF-2
• REP-9
• seasonal influenza [H3N2] vaccine
• VX-787

For more information visit http://www.researchandmarkets.com/research/pqmmkr/h3n2_infection

[ Back To TMCnet.com's Homepage ]